Sutro Biopharma (STRO) Financials: History & Chart

Sutro Biopharma, Inc.(STRO)

Biotechnology · South San Francisco, CA

$14.63-0.50 (-3.31%)

Delayed quote: Oct 6, 2026, 2:39 PM EDT

About Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

South San Francisco, CA

128 employees

www.sutrobio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jane Chung

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	45.70M	9.84M	14.52M	11.65M	9.69M	63.74M	17.40M	14.81M	8.52M
Cost of Goods Sold	1.28M	0.00	1.28M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	44.42M	9.84M	13.24M	11.65M	9.69M	63.74M	17.40M	14.81M	8.52M
Gross Profit Margin	97.2%	100.0%	91.2%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	186.04M	39.73M	42.86M	45.30M	58.15M	67.09M	85.91M	80.07M	76.44M
Research & Development	144.74M	31.70M	36.55M	36.64M	39.85M	38.33M	51.60M	71.04M	62.11M
Selling, General & Administrative	32.82M	7.83M	7.58M	8.66M	8.74M	10.34M	13.27M	9.03M	14.33M
Operating Income (EBIT)	-141.62M	-29.89M	-29.61M	-33.66M	-48.46M	-3.35M	-68.51M	-65.26M	-67.92M
Operating Margin	-309.9%	-303.8%	-203.9%	-289.0%	-499.9%	-5.2%	-393.8%	-440.7%	-797.2%
Income Before Tax (EBT)	-180.73M	-38.53M	-38.50M	-46.84M	-56.86M	-11.52M	-75.97M	-70.09M	-48.79M
Interest Income	6.90M	1.72M	1.64M	1.53M	2.01M	2.52M	3.19M	3.86M	27.04M
Interest Expense	40.06M	9.86M	9.47M	10.33M	10.41M	9.65M	10.64M	8.69M	7.91M
Other Income/Expense	-39.11M	-8.64M	-8.88M	-13.19M	-8.40M	-8.17M	-7.45M	-4.83M	19.13M
Net Income	-180.64M	-38.53M	-38.48M	-46.76M	-56.86M	-11.50M	-75.97M	-72.44M	-48.79M
Income Tax Expense	-96K	1K	-15K	-82K	0.00	-18K	0.00	2.35M	0.00
Net Profit Margin	-395.2%	-391.6%	-265.0%	-401.5%	-586.6%	-18.0%	-436.6%	-489.2%	-572.6%
EBITDA	-135.55M	-28.63M	-28.34M	-32.03M	-46.56M	-1.45M	-66.61M	-63.39M	-66.12M
EBITDA Margin	-296.6%	-290.9%	-195.1%	-275.0%	-480.3%	-2.3%	-382.9%	-428.1%	-776.1%
Depreciation & Amortization	6.06M	1.26M	1.28M	1.62M	1.90M	1.90M	1.90M	1.87M	1.80M
EPS Basic	-17.42	-2.33	-2.94	-5.45	-6.70	-1.40	-9.10	-8.80	-5.90
EPS Diluted	-17.42	-2.33	-2.94	-5.45	-6.70	-1.40	-9.10	-8.80	-5.90
Weighted Average Basic Shares	16.57M	16.57M	13.08M	8.58M	8.49M	8.46M	8.31M	8.25M	8.20M
Weighted Average Diluted Shares	16.57M	16.57M	13.08M	8.58M	8.49M	8.46M	8.31M	8.25M	8.20M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	102.48M	62.04M	153.73M	67.77M	61.88M	42.72M	42.74M	38.42M
Cost of Goods Sold	7.32M	7.22M	6.82M	8.29M	9.77M	76.96M	0.00	54.26M
Gross Profit	95.16M	54.83M	146.91M	59.48M	52.11M	-34.24M	42.74M	-15.84M
Gross Profit Margin	92.9%	88.4%	95.6%	87.8%	84.2%	-80.1%	100.0%	-41.2%
Total Operating Expenses	200.11M	293.28M	236.19M	188.43M	150.63M	36.82M	98.20M	75.64M
Research & Development	166.42M	252.04M	180.43M	137.17M	104.40M	76.96M	65.61M	54.26M
Selling, General & Administrative	41.02M	48.45M	62.58M	59.54M	56.00M	36.82M	32.59M	21.38M
Operating Income (EBIT)	-104.95M	-238.45M	-89.28M	-128.94M	-98.52M	-71.06M	-55.47M	-37.22M
Operating Margin	-102.4%	-384.3%	-58.1%	-190.3%	-159.2%	-166.3%	-129.8%	-96.9%
Income Before Tax (EBT)	-191.18M	-225.10M	-88.60M	-116.70M	-105.54M	-32.13M	-55.74M	-35.32M
Interest Income	9.25M	44.42M	14.51M	3.46M	577K	1.51M	4.07M	1.62M
Interest Expense	38.21M	31.07M	23.75M	3.35M	3.14M	3.97M	4.35M	1.60M
Other Income/Expense	-86.23M	13.36M	677K	12.24M	-7.01M	38.93M	-276K	1.91M
Net Income	-191.09M	-227.46M	-106.79M	-119.20M	-105.54M	-32.13M	-55.74M	-35.32M
Income Tax Expense	-93K	2.36M	18.19M	2.50M	0.00	0.00	0.00	0.00
Net Profit Margin	-186.5%	-366.6%	-69.5%	-175.9%	-170.6%	-75.2%	-130.4%	-91.9%
EBITDA	-97.63M	-231.24M	-82.46M	-120.66M	-93.68M	-66.76M	-50.69M	-32.68M
EBITDA Margin	-95.3%	-372.7%	-53.6%	-178.0%	-151.4%	-156.3%	-118.6%	-85.1%
Depreciation & Amortization	7.32M	7.22M	6.82M	8.29M	4.84M	4.30M	4.78M	4.54M
EPS Basic	-22.49	-29.60	-17.80	-23.50	-22.90	-9.90	-24.30	-15.50
EPS Diluted	-22.49	-29.60	-17.80	-23.50	-22.90	-9.90	-24.30	-15.40
Weighted Average Basic Shares	8.50M	7.68M	6.02M	5.07M	4.61M	3.26M	2.30M	2.29M
Weighted Average Diluted Shares	8.50M	7.68M	6.02M	5.07M	4.61M	3.26M	2.30M	2.29M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.